Nikhil Jain
Cardiovascular Disease · San Diego, CANPI 1376049114
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,266 of the $3,857 with a category attached, or 84.7%. It is spread thinly across 29 manufacturers, the largest accounting for just 20.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,566, more than ten times the $13 reported in 2020.
Across 139 payments — averaging $27.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$805
- Abbott$660
- AOP Health US, LLC$497
- E.r. Squibb & Sons, L.L.C.$192
- Edwards Lifesciences$173
- Actelion Pharmaceuticals US, Inc.$170
- plus $1K from 23 others
What the payments were for
- Travel & lodging$3549%
- Food & beverage$3,26685%
- Education$2376%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 45 | $805 |
| Abbott | 6 | $660 |
| AOP Health US, LLC | 1 | $497 |
| E.r. Squibb & Sons, L.L.C. | 11 | $192 |
| Edwards Lifesciences | 1 | $173 |
| Actelion Pharmaceuticals US, Inc. | 8 | $170 |
| Kiniksa Pharmaceuticals International, PLC | 7 | $166 |
| Amgen | 8 | $156 |
| Pfizer | 9 | $154 |
| Johnson & Johnson | 10 | $133 |
| United Therapeutics Corporation | 5 | $111 |
| Kiniksa Pharmaceuticals, Ltd. | 4 | $86 |
| Biosense Webster, Inc. | 3 | $68 |
| Cleerly, Inc. | 1 | $63 |
| Cardiva Medical, Inc. | 1 | $46 |
| Boston Scientific | 2 | $45 |
| AstraZeneca(2 entities) | 3 | $42 |
| Alnylam Pharmaceuticals Inc. | 2 | $37 |
| Bayer | 2 | $35 |
| Sanofi | 1 | $33 |
| Regeneron Healthcare Solutions, Inc. | 1 | $28 |
| Daiichi Sankyo Inc. | 1 | $25 |
| Mallinckrodt Hospital Products Inc. | 1 | $25 |
| Merck | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Boehringer Ingelheim | 1 | $18 |
| GSK | 1 | $18 |
| Daxor Corporation | 1 | $17 |
| Irhythm Technologies, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rapiblyk$995
- NAVITOR$345
- ENSITE$237
- SAPIEN 3 Ultra RESILIA$173
How this compares
$3,857 in reported general payments places this provider in the 60th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in San Diego
- Lori DanielsSan Diego$278K
- Michael WilkinsonSan Diego$145K
- Ted LoveHillsborough$102.8M
- Paul KurthSanta Barbara$6.1M
- Jason RogersSacramento$4.4M
- Matthew BudoffTorrance$3.6M
- Eric Topolla Jolla$2.2M
- Cathleen Bairey-MerzLos Angeles$1.2M
- Gagan SinghSacramento$1.2M
- Pam Taubla Jolla$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.